Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 6,500 shares, a drop of 64.1% from the December 31st total of 18,100 shares. Based on an average daily trading volume, of 32,700 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's stock are short sold.

Aziyo Biologics Stock Performance

Shares of AZYO traded down $0.21 during trading hours on Thursday, reaching $4.69. The company had a trading volume of 36,795 shares, compared to its average volume of 35,023. The firm has a 50 day simple moving average of $4.61 and a 200-day simple moving average of $6.19. Aziyo Biologics has a 12-month low of $3.37 and a 12-month high of $9.01.

Aziyo Biologics (NASDAQ:AZYO – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.07). The company had revenue of $12.39 million during the quarter, compared to analysts' expectations of $12.20 million. Aziyo Biologics had a negative net margin of 77.08% and a negative return on equity of 1,819.23%. Equities research analysts predict that Aziyo Biologics will post -2.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Insider Activity at Aziyo Biologics

In related news, Director Highcape Capital, L.P. bought 735,000 shares of the company's stock in a transaction that occurred on Monday, December 5th. The shares were purchased at an average cost of $4.75 per share, with a total value of $3,491,250.00. Following the transaction, the director now directly owns 5,597,604 shares of the company's stock, valued at approximately $26,588,619. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Aziyo Biologics news, Director Highcape Capital, L.P. purchased 735,000 shares of the firm's stock in a transaction that occurred on Monday, December 5th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $3,491,250.00. Following the purchase, the director now directly owns 5,597,604 shares in the company, valued at $26,588,619. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Matthew Ferguson purchased 22,000 shares of the firm's stock in a transaction that occurred on Monday, December 5th. The shares were acquired at an average price of $4.65 per share, with a total value of $102,300.00. Following the purchase, the chief financial officer now owns 45,217 shares in the company, valued at $210,259.05. The disclosure for this purchase can be found here. Insiders have purchased 768,098 shares of company stock valued at $3,637,112 in the last ninety days. Insiders own 39.90% of the company's stock.

Hedge Funds Weigh In On Aziyo Biologics

A hedge fund recently raised its stake in Aziyo Biologics stock. Endurant Capital Management LP raised its holdings in shares of Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) by 0.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,139,932 shares of the company's stock after acquiring an additional 6,749 shares during the quarter. Aziyo Biologics makes up 2.7% of Endurant Capital Management LP's investment portfolio, making the stock its 14th largest position. Endurant Capital Management LP owned approximately 8.37% of Aziyo Biologics worth $8,208,000 as of its most recent SEC filing. Institutional investors and hedge funds own 64.85% of the company's stock.

About Aziyo Biologics

(Get Rating)

Aziyo Biologics, Inc, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.

Recommended Stories

• Get a free copy of the StockNews.com research report on Aziyo Biologics (AZYO)
• Chevron Delights Shareholders with $75 Billion in Share Buybacks
• The Future Of E-Commerce: Analysis And New Data
• Levi Strauss Is A Good Fit For Income Investors
• 3 Small Caps That Have Big Upside
• Mullen Automotive: The Good News, The Bad And The Ugly Outlook

Receive News & Ratings for Aziyo Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aziyo Biologics and related companies with MarketBeat.com's FREE daily email newsletter.